Rebecca L Sheets

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Opinion on adventitious agents testing for vaccines: why do we worry so much about adventitious agents in vaccines?
    Rebecca L Sheets
    CAPT USPHS, USNIH NIAID DAIDS, Bethesda, MD 20892, United States
    Vaccine 31:2791-5. 2013
  2. doi request reprint Adventitious agents, new technology, and risk assessment, 19-20 May 2011, Baltimore, MD
    Rebecca Sheets
    National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
    Biologicals 40:162-7. 2012
  3. pmc Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inser
    Rebecca L Sheets
    Vaccine Research Center, NIH NIAID, Bethesda, Maryland 20892 7628, USA
    J Immunotoxicol 5:315-35. 2008
  4. ncbi request reprint Vaccine cell substrates 2004
    Rebecca Sheets
    US Public Health Service, NIH NIAID, Room 5145, 6700B Rockledge Dr MSC 7628, Bethesda, MD 20892 7628, USA
    Expert Rev Vaccines 3:633-8. 2004
  5. ncbi request reprint Assaying potency of novel vaccines. October 11-12, 2005, Bethesda, MD, USA
    Rebecca Sheets
    USPHSNIH NIAID, 6700B Rockledge Drive, Rm 5145, Bethesda, MD 20892, USA
    Expert Rev Vaccines 5:315-8. 2006
  6. pmc Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts
    Rebecca L Sheets
    U S Public Health Service, Vaccine Production Program, NIH NIAID Vaccine Research Center, Bethesda, Maryland 20892 7628, USA
    Toxicol Sci 91:610-9. 2006
  7. pmc Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts
    Rebecca L Sheets
    U S Public Health Service, Vaccine Production Program, NIH NIAID Vaccine Research Center, Bethesda, Maryland 20892 7628, USA
    Toxicol Sci 91:620-30. 2006
  8. pmc Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells
    Cheng Cheng
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 3:e25. 2007
  9. ncbi request reprint Current advances and challenges in HIV-1 vaccines
    Isaac R Rodriguez-Chavez
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 3:39-47. 2006
  10. ncbi request reprint Current advances in HIV vaccines
    M Patricia D'Souza
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 6700B Rockledge Drive, Room 5127, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 1:18-24. 2004

Collaborators

Detail Information

Publications13

  1. doi request reprint Opinion on adventitious agents testing for vaccines: why do we worry so much about adventitious agents in vaccines?
    Rebecca L Sheets
    CAPT USPHS, USNIH NIAID DAIDS, Bethesda, MD 20892, United States
    Vaccine 31:2791-5. 2013
    ..In the end, vaccinologists need to reassure the public that the vaccines they or their children receive are safe and pure and that all reasonable measures are taken to safeguard them...
  2. doi request reprint Adventitious agents, new technology, and risk assessment, 19-20 May 2011, Baltimore, MD
    Rebecca Sheets
    National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
    Biologicals 40:162-7. 2012
    ..A draft algorithm for risk assessment was discussed in terms of its applicability to a variety of potential new agents and the possibilities for improving it...
  3. pmc Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inser
    Rebecca L Sheets
    Vaccine Research Center, NIH NIAID, Bethesda, Maryland 20892 7628, USA
    J Immunotoxicol 5:315-35. 2008
    ..These data demonstrate the safety and suitability for investigational human use of Ad5 or Ad35 adenovector-based vaccine candidates at doses of up to 2 x 10(11) given intramuscularly to prevent various infectious diseases...
  4. ncbi request reprint Vaccine cell substrates 2004
    Rebecca Sheets
    US Public Health Service, NIH NIAID, Room 5145, 6700B Rockledge Dr MSC 7628, Bethesda, MD 20892 7628, USA
    Expert Rev Vaccines 3:633-8. 2004
  5. ncbi request reprint Assaying potency of novel vaccines. October 11-12, 2005, Bethesda, MD, USA
    Rebecca Sheets
    USPHSNIH NIAID, 6700B Rockledge Drive, Rm 5145, Bethesda, MD 20892, USA
    Expert Rev Vaccines 5:315-8. 2006
  6. pmc Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts
    Rebecca L Sheets
    U S Public Health Service, Vaccine Production Program, NIH NIAID Vaccine Research Center, Bethesda, Maryland 20892 7628, USA
    Toxicol Sci 91:610-9. 2006
    ..2006) to demonstrate the safety and suitability for investigational human use of DNA plasmid vaccine candidates for a variety of infectious disease prevention indications...
  7. pmc Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts
    Rebecca L Sheets
    U S Public Health Service, Vaccine Production Program, NIH NIAID Vaccine Research Center, Bethesda, Maryland 20892 7628, USA
    Toxicol Sci 91:620-30. 2006
    ..2006) to demonstrate the safety and suitability for investigational human use of DNA plasmid vaccine candidates for a variety of infectious disease prevention indications...
  8. pmc Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells
    Cheng Cheng
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 3:e25. 2007
    ..Understanding of these interactions facilitates the development of vectors that target DCs through alternative receptors that can improve safety while retaining the immunogenicity of rAd vaccines...
  9. ncbi request reprint Current advances and challenges in HIV-1 vaccines
    Isaac R Rodriguez-Chavez
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 3:39-47. 2006
    ..Simultaneously, expanded efforts continue to identify new designs that induce mucosal immunity as well as broadly neutralizing antibodies...
  10. ncbi request reprint Current advances in HIV vaccines
    M Patricia D'Souza
    Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 6700B Rockledge Drive, Room 5127, Bethesda, MD 20892, USA
    Curr HIV/AIDS Rep 1:18-24. 2004
    ..One or more candidate vaccines will likely advance into efficacy trials within the next few years, while efforts to identify new designs that induce broadly neutralizing antibodies continue with incremental success...
  11. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1638-49. 2006
    ..Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine...
  12. pmc A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 2610, Bethesda, MD 20892 3017, USA
    Vaccine 26:6338-43. 2008
    ..Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety and immunogenicity of a SARS DNA vaccine in a Phase I human study...
  13. ncbi request reprint Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads
    Heather B Jaspan
    Desmond Tutu HIV Centre, University of Cape Town, South Africa
    J Acquir Immune Defic Syndr 47:86-92. 2008
    ..This article examines these issues and proposes specific next steps to facilitate the routine inclusion of this high-priority population in preventive HIV vaccine trials as early and seamlessly as possible...